1st Counsel – Lifestyle
Author:
Decoy Therapeutics, Inc
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
April 27, 2026
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
April 9, 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
April 6, 2026
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 2, 2026
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
March 11, 2026
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
March 5, 2026